
Destroying cancer at its earliest stage
pitch_v1_importSee something off about this company?
Millions of patients each year suffer from delayed or missed diagnoses of soft tissue cancers and other conditions due to the difficulty of accurately targeting small lesions with existing image-guided tools. Current MRI-guided procedures are slow, cumbersome, and often not feasible in community hospitals, leaving many patients without timely, minimally invasive treatment options. This gap in access leads to worse outcomes, higher costs, and missed opportunities for early intervention when treatment success rates are highest.